Funda Meric-Bernstam

Research.com Recognitions

• 2025 - Research.com Best Female Scientists Award

Overview

Best Publications

• Cell-of-Origin Patterns Dominate the Molecular Classification of 10,000 Tumors from 33 Types of Cancer.

  Katherine A. Hoadley;Christina Yau;Christina Yau;Toshinori Hinoue;Denise M. Wolf

  2565
  Citations

• Efficacy of Larotrectinib in TRK Fusion–Positive Cancers in Adults and Children

  Alexander Drilon;Theodore W. Laetsch;Shivaani Kummar;Steven G. DuBois

  2422
  Citations

• PD-L1 Expression in Triple-Negative Breast Cancer

  Elizabeth A Mittendorf;Anne V Philips;Funda Meric-Bernstam;Na Qiao

  1486
  Citations

• KRASG12C Inhibition with Sotorasib in Advanced Solid Tumors.

  David S. Hong;Marwan G. Fakih;John H. Strickler;Jayesh Desai

  1300
  Citations

• Genomic and Functional Approaches to Understanding Cancer Aneuploidy

  Alison M. Taylor;Alison M. Taylor;Juliann Shih;Gavin Ha;Gavin Ha;Galen F. Gao

  1116
  Citations

• Clonal evolution in breast cancer revealed by single nucleus genome sequencing

  Yong Wang;Jill Waters;Marco L. Leung;Anna Unruh

  1116
  Citations

• Metformin and Pathologic Complete Responses to Neoadjuvant Chemotherapy in Diabetic Patients With Breast Cancer

  Sao Jiralerspong;Shana L. Palla;Sharon Hermes Giordano;Funda Meric-Bernstam

  1091
  Citations

• Targeting the PI3K pathway in cancer: are we making headway?

  Filip Janku;Timothy A. Yap;Funda Meric-Bernstam

  921
  Citations

• Recommendations for the use of next-generation sequencing (NGS) for patients with metastatic cancers: a report from the ESMO Precision Medicine Working Group.

  F. Mosele;J. Remon;J. Mateo;C. B. Westphalen

  909
  Citations

• Pathogenic Germline Variants in 10,389 Adult Cancers

  Kuan-Lin Huang;R Jay Mashl;Yige Wu;Deborah I Ritter

  848
  Citations

• Differential response to neoadjuvant chemotherapy among 7 triple-negative breast cancer molecular subtypes

  Hiroko Masuda;Keith A. Baggerly;Ying Wang;Ya Zhang

  802
  Citations

• Targeting the mTOR Signaling Network for Cancer Therapy

  Funda Meric-Bernstam;Ana Maria Gonzalez-Angulo

  802
  Citations

• Efficacy of RAD001 (Everolimus) and Octreotide LAR in Advanced Low- to Intermediate-Grade Neuroendocrine Tumors: Results of a Phase II Study

  James C. Yao;Alexandria T. Phan;David Z. Chang;Robert A. Wolff

  763
  Citations

• HER kinase inhibition in patients with HER2- and HER3-mutant cancers.

  David M. Hyman;Sarina A. Piha-Paul;Helen Won;Jordi Rodon

  704
  Citations

• Incidence and Outcome of BRCA Mutations in Unselected Patients with Triple Receptor-Negative Breast Cancer

  Ana M. Gonzalez-Angulo;Kirsten M. Timms;Shuying Liu;Huiqin Chen

  676
  Citations

• Emergence of constitutively active estrogen receptor-α mutations in pretreated advanced estrogen receptor positive breast cancer

  Rinath Jeselsohn;Roman Yelensky;Gilles Buchwalter;Gilles Buchwalter;Garrett Frampton

  668
  Citations

• Erratum: Comprehensive Characterization of Cancer Driver Genes and Mutations (ARTICLE (2018) 173(2) (371–385), (S009286741830237X), (10.1016/j.cell.2018.02.060))

  Matthew H. Bailey;Collin Tokheim;Eduard Porta-Pardo;Sohini Sengupta

  589
  Citations

• A pan-cancer proteomic perspective on The Cancer Genome Atlas

  Rehan Akbani;Patrick Kwok Shing Ng;Henrica M.J. Werner;Maria Shahmoradgoli

  588
  Citations

• High risk of recurrence for patients with breast cancer who have human epidermal growth factor receptor 2-positive, node-negative tumors 1 cm or smaller.

  Ana Maria Gonzalez-Angulo;Jennifer K Litton;Kristine R Broglio;Funda Meric-Bernstam

  535
  Citations

• Beta-Blocker Use Is Associated With Improved Relapse-Free Survival in Patients With Triple-Negative Breast Cancer

  Amal Melhem-Bertrandt;Mariana Chavez-MacGregor;Xiudong Lei;Erika N. Brown

  513
  Citations